Agent Capital
Venture capitalActively deployingWaltham · Pre-Seed–Late Stage · 22 people tracked
Also known as AGENT CAPITAL, LLC
Investment thesis
Agent Capital is a healthcare-focused venture firm backing novel and differentiated therapeutics aimed at unmet patient needs. It invests across all stages of development and collaborates with scientists, entrepreneurs, and co-investors to advance the next generation of healthcare innovations. The firm takes a balanced investment approach grounded in an understanding of biopharma pipeline pressures, proactively guiding biotech companies toward key milestones and exits. Its typical areas of focus include rare diseases, oncology, neurology, and immunology, and it is willing to invest regardless of stage or investment type.
Source: firm website, verified Aug 25, 2026.
Team · 22 people
from the firm's website
Founder mafia
2 people who came through Agent Capital went on to found or lead other companies.
What they invest in
from 45 of 75 portfolio companiesBiotech ×38Healthtech ×27Medical Devices ×9Deep Tech ×7AI & Machine Learning ×6Digital Health ×5Enterprise Software ×2Future of Work ×2
HQs:United States×30United Kingdom×2Japan×1Kenya×1
Investments · 75 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 42024 · 22023 · 12022 · 32021 · 12019 · 42017 · 12015 · 12014 · 121 dated
HealthtechBoston, US
John Flavin(Director)Lucio Iannone(Director)
BoardDavid Steinberg(Executive Officer, Director)Christoph Westphal(Director)Jak Knowles(Director)
Board seatGeeta Vemuri· per SEC Form D · $22M raise · filed Jul 2019
Co-investorsLongwood FundRA Capital
BiotechWarrington, US
Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)John Tattory(Executive Officer)George Cox(Executive Officer)
Board seatBruce Peacock· per SEC Form D · $26.4M raise · filed Dec 2019
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Board seatJohn Orloff· per SEC Form D
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersQuan CapitalSR One Capital Management+1 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Nerissa Kreher(Executive Officer)Kory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)Natarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesMPM BioImpactRoche Venture FundTCG Crossover
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in
BoardStuart Lawson(Director)
Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more
Bob Parsons(Founder)in
Co-investorsAnsa CapitalCitta CapitalCrimson Investment FundCyverse CapitalFiddlehead VenturesHealthtech Capital+6 more
Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases.
BiotechSouth San Francisco, US
Bernard Coulie(Executive Officer, Director)Johannes Hull(Executive Officer)Eric Lefebvre(Executive Officer)
BoardKevin Raidy(Director)Neil Exter(Director)inCharles Homcy(Director)
Co-investorsMenlo VenturesThird Rock Ventures
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)
Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)Michael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)Lee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)
Co-investorsAtlas VentureOrbiMedCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures
āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.
BiotechHealthtechBurlingame, US
Pankaj Bhargava(Founder & Chief Executive Officer)Victoria Smith(Chief Scientific Officer)Deborah Wenkert(Chief Medical Officer)Joseph Sarret(Acting Chief Operating Officer)Brian Shuster(Acting Chief Business Officer)
Co-investorsMPM BioImpact
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Susan B Dillon(Executive Officer, Director)Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)Mark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)
Board seatBruce Peacock· per SEC Form D · $5M raise · filed Jan 2020
Co-investorsAvego BioScience CapitalHealthCap
Luxembourg
Joanna Shields(Director, Executive Officer)Jean Raby(Director)Olivier Brandicourt(Director)Nick Keher(Executive Officer)Susan Liautaud(Director)Ivan Griffin(Executive Officer)
Board seatJohn Orloff· per SEC Form D · filed Sep 2022
The page presents Pinco Casino, an online gambling platform offering slots, live casino, table games, and sports betting with a Turkish-language interface.
ConsumerGamingBoston, US
Board seatGeeta Vemuri· per SEC Form D
Co-investorsAstellas Venture Management LLCDC Investment PartnersSolasta VenturesUTokyo Innovation Platform Co. Ltd.Longwood Fund
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)
BoardMargarita Chavez(Director)Eran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)
Board seatBruce Peacock· per SEC Form D
Co-investorsAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures FundSolasta Ventures+1 more
Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases.
BiotechHealthtechMedical DevicesBedford, US
W. James O'Shea(Director)Kevin Hanley(Executive Officer)Richard L. Lindstrom(Director)Michael Goldstein(Executive Officer)Amarpreet Sawhney(Director)Daniel Bollag(Executive Officer)
Board seatBruce Peacock· per SEC Form D · $37.5M raise · filed Mar 2019
Co-investorsAscension VenturesSofinnova VenturesSV Health InvestorsTop Corner Capital
BiotechMt. Arlington, US
Paul Chaney(Executive Officer, Director)
BoardAbbie Celniker(Director)inDavid Guyer(Director)Kevin Starr(Director)Lutz Giebel(Director)
Board seatBruce Peacock· per SEC Form D · $47.3M raise · filed Apr 2019
Co-investorsAstellas Venture Management LLCThird Rock Ventures
Orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities.
BiotechHealthtechLongevity
Co-investorsHumboldtOlive Tree Capital
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease.
BiotechHealthtechPhiladelpia, US
Errik Anderson(Executive Officer, Director)Ross Leimberg(Executive Officer, Director)
BoardJoshua Brandt(Director)Geeta Vemuri(Executive Officer, Director)in
Co-investors82VS
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.
BiotechDeep TechHealthtech
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundSV Life SciencesDementia DiscoveryLightstone Ventures+2 more
Cyrus Bio is a computational drug discovery company that uses protein design, deep mutagenesis, and modeling algorithms to engineer naturally occurring proteins into therapeutics.
AI & Machine LearningBiotechDeep TechSeattle, US
Javier Castellanos(Executive Officer, Director)Yifan Song(Executive Officer, Director)
BoardLucas Nivon(Executive Officer, Director)
Co-investorsAnzu PartnersArgonautic VenturesiSelect FundOrbiMedSPRINGROCK VENTURESStrawberry Creek Ventures+2 more
Dragonfly develops immunotherapies, including B and T cell depleters and immune engagers, targeting autoimmune and inflammatory diseases, oncology, fibrosis, and neuro-inflammation.
BiotechHealthtech
Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.
Enterprise SoftwareGovTechSaaSNairobi, KE
Co-investors4Di CapitalInovia CapitalBase10 PartnersCasdin CapitalInvusNextech Invest+3 more
Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.
Crypto & Web3Data & Infrastructure
Co-investorsDigital Currency GroupBase10 PartnersCasdin CapitalInovia CapitalInvusNextech Invest+3 more
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesBase10 PartnersCasdin CapitalInovia Capital+5 more
Flare Therapeutics is a drug discovery company developing small molecule therapies that target transcription factors to restore transcriptional control disrupted by cancer.
BiotechHealthtech
Co-investorsNextech InvestPfizer Venture InvestmentsShangBay Capital LLC
Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.
BiotechDigital HealthHealthtechBoulder, US
Co-investorsCivilization Ventures Management, Llc
GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.
BiotechHealthtechNewton, US
Ganesh V. Kaundinya(President & CEO)in
Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesRoche Venture FundSixty Degree CapitalSofinnova Partners+1 more
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin M. Rollins(Executive Officer, Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Harold E. "Barry" Selick(Chief Executive Officer & Director)
Co-investorsPoint72Baruch Future VenturesInVivium CapitalRidgeback Capital
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Co-investorsAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresGimv
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsDC Investment PartnersLongwood FundMedical Excellence CapitalNovartis Venture FundOno Venture Investment, Inc.Solasta Ventures+2 more
Ivee provides AI training, strategy, and policy development services for organizational teams, including custom training programs, AI audits, policy writing, and tool integration guidance.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareFuture of WorkHR TechLondon, GB
Lydia Miller(Founder)inAmelia Miller(Founder)in
Co-investorsTechstarsFJ LabsGaingelshumbitionLooking Glass CapitalTribe Capital
Jana Care offers a smartphone-enabled at-home blood testing system using its Aina device, paper test strips, and a mobile app to detect key biomarkers for chronic disease management.
Digital HealthHealthtechMedical DevicesWatertown, US
Sidhant Jena(Executive Officer, Director)Timothy Richards(Executive Officer)Richard Williams(Executive Officer)Anh Hoang-Lindsay(Executive Officer, Director)Michal Depa(Executive Officer, Director)
BoardEhsan Jabbarzadeh(Director)
Co-investorsFirst Avenue VenturesIAG Capital PartnersPatamar CapitalThe A-Team
Mediartx develops novel therapies for patients with fibrotic diseases.
BiotechMedical DevicesBoston, US
Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)
Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+2 more
Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.
BiotechDeep TechMedical DevicesBerkeley, US
Brian Thomas(Executive Officer, Director, Promoter)
BoardAndrew Farquharson(Director)Jak Knowles(Director)
Co-investorsCatalio Capital Management, LPRA CapitalSozo VenturesHumboldtInCube VenturesLeaps by Bayer+1 more
Nu-Tek BioSciences manufactures 100% animal-free specialty yeast extracts, peptones, and hydrolysates used in cell culture media and biologic production.
Advanced ManufacturingBiotechNew Materials
Co-investors1315 Capital
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Co-investorsAndreessen HorowitzARCH Venture PartnersiGlobe PartnersNewpath PartnersREDMILE
Orbus Therapeutics is a clinical-stage biopharmaceutical company developing eflornithine (DFMO), an oral ODC inhibitor, as a cancer therapy.
BiotechHealthtechAptos, US
Jason Levin(Founder, Director and Chief Executive Officer)Jason D. Levin(Executive Officer, Director)Robert M. Myers(Executive Officer, Director)
BoardMichael Wasserman(Director)Patrick Enright(Director)Elisha (Terry) Gould(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersLongitude Capital
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)Steven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundBaillie GiffordORI Capital+1 more
Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform.
BiotechHealthtechWayne, US
Co-investorsFrazier Life Sciences
BiotechSan Diego, US
Helge Zieler(Director, Executive Officer)
BoardJ. Todd Mitchell(Director)Matthew Korenberg(Director)Matthew Reber(Director)Wes Kaupinen(Director)
Co-investors1315 Capital
Developing SKY-0515 for Huntington's Disease; running the global pivotal FALCON-HD clinical trial.
Co-investorsGood Growth CapitalShangBay Capital LLC
Skyhawk Therapeutics develops RNA-targeting small molecule drugs using its SKYSTAR platform to modify RNA expression, addressing diseases in neurology, oncology, and fibrotic conditions.
BiotechDeep TechWaltham, US
Kathleen McCarthy(Founder)
Co-investorsDns CapitalGood Growth CapitalGreatPoint Ventures
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Matthew Fust(Director)Amrit Nagpal(Director)
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesBlue Owl Capital+8 more
TRexBio develops Treg-focused biologic therapeutics for autoimmune and inflammatory diseases, using its Deep Biology Platform to analyze regulatory T cell behavior in human tissues and identify therapeutic targets.
AI & Machine LearningBiotechHealthtech
Co-investorsAvego BioScience CapitalDelos CapitalPfizer Venture Investments
Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US
Alice Zhang(Founder/CEO)inJason Chen(Cofounder)Emily Ripka(Head of Product & Engineering)
Co-investorsBOLD LongevityDraper AssociatesFitz Gate VenturesGreat Oaks Venture CapitalKarlin VenturesLifeforce Capital+5 more
Co-investorsDC Investment PartnersLongwood FundPfizer Venture InvestmentsQuan Capital
Pyxis Oncology develops clinical-stage cancer therapeutics, including antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies, aimed at difficult-to-treat cancers.
BiotechHealthtech
Co-investorsLongwood FundPfizer Venture Investments
Vittoria Biotherapeutics is a clinical-stage company developing next-generation autologous CAR T-cell immunotherapies for oncology and immunology, built on its Senza5 platform that uses CD5 signaling modulation and a 5-day manufacturing process.
BiotechMedical Devices
Co-investorsBioAdvanceGlobal BioAccess Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 10
IPOs and acquisitions across the tracked portfolioPyxis OncologyNASDAQ: PYXSWindtree Therapeutics INC /DeOTC: WINTZenas BiopharmaNASDAQ: ZBIOEntrada Therapeutics, Inc.NASDAQ: TRDAFreenomeNASDAQ: FRNMGodaddyNYSE: GDDYPliant TherapeuticsNASDAQ: PLRXPrecision BioSciencesNASDAQ: DTILQ32 BioNASDAQ: QTTBImcheckacq. by Clementia
Portfolio news
latest coverage across their companiesAlveus Therapeutics · fiercebiotech.com · Aug 12, 2026
Metagenomi · za.investing.com · Aug 11, 2026
Orchard Therapeutics · x.com · Aug 8, 2026
Precision BioSciences · tradingkey.com · Aug 6, 2026
Q32 Bio · stocktitan.net · Aug 5, 2026
Flare · coindesk.com · Jul 30, 2026
Flare · allsci.com · Jul 1, 2026
Flare Therapeutics · allsci.com · Jul 1, 2026
Frequently asked questions
- How many investments has Agent Capital made?
- Agent Capital has 28 tracked investments.
- What stage does Agent Capital invest at?
- Agent Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Agent Capital focus on?
- Agent Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Agent Capital located?
- Agent Capital is headquartered in Waltham, US.
- Does Agent Capital lead rounds?
- Yes, Agent Capital leads investment rounds.
- Who does Agent Capital co-invest with?
- Agent Capital most often shares deals with Ansa Capital, Good Growth Capital, Octave Ventures Llc, among 13 tracked co-investors.
Images
Co-investors · 12
Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.
OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Trinity Ventures is an early-stage venture capital firm that invests in mission-driven entrepreneurs and their companies.
Omega Funds invests in venture capital and growth equity opportunities across the life sciences sector.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Bain Capital Life Sciences, founded in 2016, invests in biopharmaceutical, medical device, diagnostic, and life science tool companies globally, focusing on companies addressing unmet medical needs and driving medical innovation.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
Cofounders Capital is a North Carolina-based venture firm that leads seed-stage investments in B2B software companies across the southeastern United States.
AbbVie Ventures is the corporate venture capital arm of biopharmaceutical company AbbVie, investing in early-stage companies in oncology, immunology, and neurodegenerative diseases that complement the parent company's research and development pipeline.
Firms observed investing alongside Agent Capital, from public investor directories. Shared companies are the overlap with Agent Capital's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Accelmed Partners is a healthcare technology investment firm that applies a private equity approach to a sector traditionally served by venture and early-stage growth investors, focusing on tools & diagnostics, digital health, and tech-enabled services.